PROSTATE CANCER: EPIDEMOLOGIC AND CLINICAL MARKERS

$291,807P50FY2002CANIH

University Of Texas Md Anderson Can Ctr, Houston TX

Investigators

Linked publications & trials

Paper 36112348 Paper 26080435 Paper 25832466 Paper 24061515 Paper 22753310 Paper 22419652 Paper 21764858 Paper 21526653 Paper 21483646 Paper 21437722 Paper 20812760 Paper 20551894 Paper 20360964 Paper 19855158 Paper 19853370 Paper 19671758 Paper 19508243 Paper 19458761 Paper 19395652 Paper 19390667 Paper 19349357 Paper 19244175 Paper 19224553 Paper 19141644 Paper 19081821 Paper 19016654 Paper 18841158 Paper 18708358 Paper 18620062 Paper 18618693 Paper 18618013 Paper 18583538 Paper 18559590 Paper 18490922 Paper 18476810 Paper 18455122 Paper 18347159 Paper 18324626 Paper 18303481 Paper 18247399 Paper 18237448 Paper 18030366 Paper 17908974 Paper 17700537 Paper 17699763 Paper 17638862 Paper 17634423 Paper 17548657 Paper 17485298 Paper 17409287 Paper 17317833 Paper 17210693 Paper 17177290 Paper 17160554 Paper 17016557 Paper 17013882 Paper 16988946 Paper 16984732 Paper 16889804 Paper 16867216 Paper 16860740 Paper 16860739 Paper 16802288 Paper 16798743 Paper 16757703 Paper 16736511 Paper 16722773 Paper 16581960 Paper 16564177 Paper 16510583 Paper 16452199 Paper 16357162 Paper 16354589 Paper 16322225 Paper 16288027 Paper 16278478 Paper 16260620 Paper 16258090 Paper 16211233 Paper 16208706 Paper 16203779 Paper 16183931 Paper 16183930 Paper 16172168 Paper 16026649 Paper 16024620 Paper 15994949 Paper 15972964 Paper 15948138 Paper 15867367 Paper 15867366 Paper 15805270 Paper 15799828 Paper 15767363 Paper 15713737 Paper 15681844 Paper 15661540 Paper 15622688 Paper 15558296 Paper 15542852

Abstract

A critical goal in prostate cancer (PC) research is to identify epidemiological, clinical and molecular markers related to PC progression. We propose to conduct a follow-up study of 1200 PC patients of all ethnicities seen at U.T.M.D. Anderson Cancer Center between 1990 and 2000. These men are participants in our ongoing epidemiological studies for whom we have collected baseline clinical and epidemiological information and for whom banked specimens (DNA and tissue) are available. The objective is to identify clinical, lifestyle, and genetic factors that may play a role in disease progression. Our first aim is to evaluate baseline epidemiologic (smoking, BMI, family history of PC), clinical (stage, Gleason score, tumor volume) and treatment parameters and their impact on PC progression. We will collect information on health status through telephone interviews. Recurrence, biochemical failure, and death will be verified through medical records and death certificates. Aim 2 will evaluate genetic susceptibility by genotyping patients for polymorphic genes related to hormone metabolism: androgen receptor, 5-alpha-reductase type II, CYPO17, CYP3A4, 3-beta-hydroxysteroid dehydrogenase type II, and vitamin D receptor. In aim 3, we will create tissue microarrays to allow the analysis of gene expression by in situ hybridization for a panel for tumor progression markers (e.g., MMP-2, MMP-9, VEGF, and E-cadherin) in a subset of 375 cases of indifferent ethnicity (200 whites, 100 African Americans, and 75 Hispanics). Finally, we will integrate these molecular, epidemiologic and clinical data to investigate how the interplay between these characteristics modifies PC progression. Findings from this project could be useful in identifying patients at high risk of PC progression and could assist clinicians in determining the most appropriate strategy.

View original record on NIH RePORTER →